Agile Therapeutics (AGRX) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to loss of $0.12 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 4.76%. A quarter ago, it was expected that this developer of prescription contraceptive products for women would post a loss of $0.22 per share when it actually produced a loss of $0.20, delivering a surprise of 9.09%.
Over the last four quarters, the company has surpassed consensus EPS estimates three times.
Agile Therapeutics, which belongs to the Zacks Medical – Generic Drugs industry, posted revenues of $1.19 million for the quarter ended June 2021, missing the Zacks Consensus Estimate by 18.28%. This compares to zero revenues a year ago.
The sustainability of the stock’s immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management’s commentary on the earnings call.
Agile Therapeutics shares have lost about 59.6% since the beginning of the year versus the S&P 500’s gain of 17.5%.
What’s Next for Agile Therapeutics?
While Agile Therapeutics has underperformed the market so far this year, the question that comes to investors’ minds is: what’s next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company’s earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Agile Therapeutics was unfavorable. While the magnitude and direction of estimate revisions could change following the company’s just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see
the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here
.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.18 on $4.8 million in revenues for the coming quarter and -$0.75 on $15.09 million in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical – Generic Drugs is currently in the bottom 29% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Time to Invest in Legal Marijuana
If you’re looking for big gains, there couldn’t be a better time to get in on a young industry primed to skyrocket from $17.7 billion back in 2019 to an expected $73.6 billion by 2027.
After a clean sweep of 6 election referendums in 5 states, pot is now legal in 36 states plus D.C. Federal legalization is expected soon and that could be a still greater bonanza for investors. Even before the latest wave of legalization, Zacks Investment Research has recommended pot stocks that have shot up as high as +285.9%.
You’re invited to check out
Zacks’ Marijuana Moneymakers
:
An Investor’s Guide
. It features a timely Watch List of pot stocks and ETFs with exceptional growth potential.
Today, Download Marijuana Moneymakers FREE >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report